A New Era for Sickle Cell Disease, Acute Porphyria, and More

By Basem M. William, MD On Monday, the Director of the Division of Hematology Products in the Office of Hematology and Oncology Products at the U.S. Food and Drug Administration (FDA), Ann Farrell, MD, chaired the two special ASH-FDA Joint Symposia focusing on new...

Best Donor Choice: It’s in the Eye of the Beholder!

By Basem M. William, MD One of the major leaps in hematopoietic stem cell transplantation (HSCT) is the increasingly successful use of alternative donors, thereby allowing the delivery of a potentially curative transplant to approximately 75 percent of patients who do...
The Roman God of Portals and More

The Roman God of Portals and More

By Binod Dhakal, MD, MS In 1951 a renowned hematologist from Harvard University, William Dameshek, MD, wrote an editorial in Blood providing seminal insight into myeloproliferative neoplasms (MPNs) — a group of disorders characterized by expansion of different myeloid...

A Quantum Leap in Myeloma Therapy

By Binod Dhakal, MD, MS More than a century ago, the brilliant physicist Max Planck investigated an obscure subject and sparked a revolution in physics. A profoundly conservative thinker, Planck had to disavow some orthodox theoretical ideas to assume that the total...

Lymphoma Roundup: Verdict on This Year’s Annual Meeting

By Basem M. William, MD Since Thomas Hodgkin’s initial characterization of lymphomas in 1832 and the first administration of mustard to a patient with lymphoma 100 years later amid the secrecy of a World War II gas program, much has changed. Multiple recurrent themes...

Update on ASH Immunotherapies Initiatives

The field of immunotherapy has generated novel immune-based strategies and improved the utility of existing treatment options for various hematologic diseases. As such, ASH has had an enduring interest in improving immunotherapies for all hematologic diseases. This is...